Business Context and Reporting Period
This Form 8-K is a current report filed by ADVENTRX Pharmaceuticals, Inc. (not Savara Inc.) on January 31, 2006. The filing discloses the entry into a material definitive agreement regarding executive compensation adjustments approved by the Compensation Committee.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation changes.
| Officer | Position | 2005 Base Salary | 2006 Base Salary | Stock Options Granted | Exercise Price |
|---|---|---|---|---|---|
| Joan M. Robbins, Ph.D. | CTO, EVP | $230,000 | $250,000 | 100,000 | $4.75 |
| Carrie E. Carlander | CFO, VP Finance | $180,000 | $200,000 | 80,000 | $4.75 |
| Brian M. Culley | VP Business Dev. | $170,000 | $200,000 | 80,000 | $4.75 |
Material Changes
- Salary Increases: Annual base salaries for three officers were increased retroactively effective January 1, 2006, following a review of performance and competitive market data.
- Equity Grants: Ten-year non-qualified stock options were granted under the 2005 Equity Incentive Plan. Options vest 25% on the first anniversary and monthly thereafter.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The only unusual item noted is the specific timing of the compensation adjustments and the vesting schedule of the new options.
Investor Verification Checklist
- Verify the company name is ADVENTRX Pharmaceuticals, Inc., not Savara Inc.
- Confirm the total number of shares subject to new options (260,000) and the exercise price ($4.75).
- Review the 2005 Equity Incentive Plan terms to understand dilution impact.
- Check subsequent filings for the actual vesting commencement and any further compensation changes.